Lu S - Search Results

1

Lu S. Lu S. Curr Opin Immunol. 2009 Jun;21(3):346-51. doi: 10.1016/j.coi.2009.05.016. Epub 2009 Jun 6. Curr Opin Immunol. 2009. PMID: 19500964 Free PMC article. Review.

2

Fc Receptor-Mediated Activities of Env-Specific Human Monoclonal Antibodies Generated from Volunteers Receiving the DNA Prime-Protein Boost HIV Vaccine DP6-001.

Costa MR, Pollara J, Edwards RW, Seaman MS, Gorny MK, Montefiori DC, Liao HX, Ferrari G, Lu S, Wang S. Costa MR, et al. Among authors: lu s. J Virol. 2016 Oct 28;90(22):10362-10378. doi: 10.1128/JVI.01458-16. Print 2016 Nov 15. J Virol. 2016. PMID: 27630232 Free PMC article.

3

DNA prime-protein boost using subtype consensus Env was effective in eliciting neutralizing antibody responses against subtype BC HIV-1 viruses circulating in China.

Zhang M, Zhang L, Zhang C, Hong K, Shao Y, Huang Z, Wang S, Lu S. Zhang M, et al. Among authors: lu s. Hum Vaccin Immunother. 2012 Nov 1;8(11):1630-7. doi: 10.4161/hv.21648. Epub 2012 Oct 30. Hum Vaccin Immunother. 2012. PMID: 23111170 Free PMC article.

4

Immunogenicity of DNA vaccines in humans: it takes two to tango.

Lu S. Lu S. Hum Vaccin. 2008 Nov-Dec;4(6):449-52. doi: 10.4161/hv.4.6.6179. Epub 2008 Nov 28. Hum Vaccin. 2008. PMID: 18443427 Review.

5

Contribution of TLR4 and MyD88 for adjuvant monophosphoryl lipid A (MPLA) activity in a DNA prime-protein boost HIV-1 vaccine.

Pouliot K, Buglione-Corbett R, Marty-Roix R, Montminy-Paquette S, West K, Wang S, Lu S, Lien E. Pouliot K, et al. Among authors: lu s. Vaccine. 2014 Sep 3;32(39):5049-56. doi: 10.1016/j.vaccine.2014.07.010. Epub 2014 Jul 18. Vaccine. 2014. PMID: 25045815 Free PMC article.

6

Polyvalent AIDS vaccines.

Lu S, Grimes Serrano JM, Wang S. Lu S, et al. Curr HIV Res. 2010 Dec;8(8):622-9. doi: 10.2174/157016210794088290. Curr HIV Res. 2010. PMID: 21054250 Free PMC article. Review.

7

Levels of N-linked glycosylation on the V1 loop of HIV-1 Env proteins and their relationship to the antigenicity of Env from primary viral isolates.

Huang Z, Chou A, Tanguay J, Shen S, Mboudjeka I, Chou TH, Lu S, Wang S. Huang Z, et al. Among authors: lu s. Curr HIV Res. 2008 Jun;6(4):296-305. doi: 10.2174/157016208785132518. Curr HIV Res. 2008. PMID: 18691028

8

The safety and tolerability of an HIV-1 DNA prime-protein boost vaccine (DP6-001) in healthy adult volunteers.

Kennedy JS, Co M, Green S, Longtine K, Longtine J, O'Neill MA, Adams JP, Rothman AL, Yu Q, Johnson-Leva R, Pal R, Wang S, Lu S, Markham P. Kennedy JS, et al. Among authors: lu s. Vaccine. 2008 Aug 18;26(35):4420-4. doi: 10.1016/j.vaccine.2008.05.090. Epub 2008 Jun 25. Vaccine. 2008. PMID: 18588934 Free PMC article. Clinical Trial.

9

Reduced MyD88 dependency of ISCOMATRIX™ adjuvant in a DNA prime-protein boost HIV vaccine.

Buglione-Corbett R, Pouliot K, Marty-Roix R, Li W, West K, Wang S, Morelli AB, Lien E, Lu S. Buglione-Corbett R, et al. Among authors: lu s. Hum Vaccin Immunother. 2014;10(4):1078-90. doi: 10.4161/hv.27907. Epub 2014 Feb 10. Hum Vaccin Immunother. 2014. PMID: 24513632 Free PMC article.

10

Combination DNA plus protein HIV vaccines.

Lu S. Lu S. Springer Semin Immunopathol. 2006 Nov;28(3):255-65. doi: 10.1007/s00281-006-0028-1. Epub 2006 Sep 21. Springer Semin Immunopathol. 2006. PMID: 17021720 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

15,955 results

Search Page